natgillin/translations-raw huggingface dataset:
Marker vaccine according to claim 8, characterised in that the serological analytical method is based upon an enzyme immunoassay (EIA), preferably an enzyme-linked immunosorbent assay (ELISA), whereby antibodies that bind specifically to either the modified and/or disease-associated TAV-epitope are used. 
Marker cjepivo skladu s patentnim zahtjevom 8, naznačeno time što je serološka analitička metoda temeljena na enzimskom imunoodređivanju (EIA), poželjno kompetitivnom enzimom-obilježenom imunokemijskom određivanju (ELISA), pri čemu se koriste protutijela koja se specifično vežu za bilo modificirani i/ili s bolešću povezani TAV-epitop.
Pharmaceutical composition comprising the marker vaccine according to any one of claims 1 to 11 with a pharmaceutically acceptable carrier. 
Farmaceutski sastav sadrži marker cjepivo u skladu s bilo kojim od patentnih zahtjeva 1 do 11 s farmaceutski prihvatljivim nosačem.
Marker vaccine according to any one of claims 1 to 11 for use as a medicament in the prophylactic treatment (vaccination), preferably via intramuscular injection or oral application, of classical swine fever. 
Marker cjepivo u skladu s bilo kojim od patentnih zahtjeva 1 do 11 za uporabu kao lijek u zaštitnom liječenju (cijepljenju) klasične svinjske groznice, poželjno putem intramuskularne injekcije ili oralnom primjenom.
Identification device for wood according to claim 1, characterized in that said antenna (3) is made of a thin and flat laminate covered on both sides with a thin layer of a conductive material, preferably with copper, aluminium or similar, wherein each conductive layer is formed as a spiral and wherein all conductive layers together represent a bipolar antenna (3), which is surrounded with said outer part (A) of the device, thereby forming a single integral element. 
Identifikacijski uređaj za drvo prema zahtjevu 1, naznačen time da je navedena antena (3) izrađena od tankog i ravnog laminata prekrivenog s obje strane tankim slojem vodljivog materijala, po mogućnosti bakra, aluminija ili slično, pri čemu je svaki vodljivi sloj izveden kao spirala (zavojnica) i pri čemu svi vodljivi slojevi zajedno čine bipolarnu antenu (3) koja je okružena navedenim vanjskim dijelom (A) uređaja, pri tome čineći jednostruki integralni element. .
Identification device for wood according to claim 2, characterized in that said laminate for antenna (3) is made of a fibre mesh-work, preferably of a cotton mesh-work, optionally reinforced by means of a web of artificial fibres such as glass fibres, and reinforced by means of a binding agent, preferably phenol or epoxy resin. 
Identifikacijski uređaj za drvo prema zahtjevu 2, naznačen time da je navedeni laminat za antenu (3) izrađen od vlaknaste mrežice, po mogućnosti pamučne mrežice, po želji ojačane mrežom umjetnih vlakana poput staklenih vlakana i vezivnim sredstvom, po mogućnosti fenolom ili epoksidnom smolom.
Identification device for wood according to any of the preceding claims, characterized in that a plurality of said identification devices may be stacked one upon other in the sense of a magazine that can be used with a device for driving fixing elements. 
Identifikacijski uređaj za drvo prema bilo kojem od prethodnih zahtjeva, naznačen time da je određeni broj navedenih identifikacijskih uređaja naslagan jedan na drugi u smislu robe na skladištu koju može obraditi uređaj za uvođenje elemenata za pričvršćivanje.
The aryloazol-2-yl-cyanoethylamine for use according to claim 12, wherein the helminth is Haemonchus contortus, Ostertagia circumcincta, Trichostrongylus axei, Trichostrongylus colubrifromis, Cooperia curtcei, Nematodirus Battus and combinations thereof. 
Ariloazol-2-il-cijanoetilamin za uporabu prema zahtjevu 12, naznačen time, da helmint je Haemonchus contortus, Ostertagia circumcincta, Trichostrongylus axei, Trichostrongylus colubrifromis, Cooperia curtcei, Nematodirus Battus, i njihove kombinacije.
A method for increasing the pH of an aqueous suspension containing from 25 to 62 vol. % of at least one calcium carbonate-comprising material and having a pH in the range of between 8.5 and 11, characterized in that the method involves the step of adding 2-((1-methylpropyl)amino)ethanol to the suspension in an amount, so that the pH of the suspension is increased by at least 0.3 pH units and, at the same time, the suspension conductivity change is not more than 100 µS/cm per pH unit, and characterized in that said 2-((1-methylpropyl)amino)ethanol is added to said suspension in an amount of from 500 to 15000 mg, per liter of the aqueous phase of said suspension. 
Postupak povećavanja pH vodene suspenzije koja sadrži 25 do 62 vol.% barem jednog materijala s kalcijevim karbonatom i ima pH između 8,5 i 11, naznačen time da postupak uključuje korak dodavanja 2-((1-metilpropil)amino)etanola u suspenziju u količini za povećanje pH otopine za najmanje 0,3 pH jedinice, pri čemu promjena vodljivosti otopine nije veća od 100 µS/cm po jedinici pH, naznačen time da je navedeni 2-((1-metilpropil)amino)etanol dodan u navedenu otopinu u količini od 500 do 15000 mg, po litri vodene faze navedene otopine.
Method according to claim 1, characterized in that said 2-((1-methylpropyl)amino)ethanol additive is added as a water based solution to the calcium carbonate-comprising material. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time da je navedeni aditiv 2-((1-metilpropil)amino)etanol dodan kao otopina na bazi vode materijalu koji sadrži kalcijev karbonat.
Method according to any one of the preceding claims, characterized in that following the addition of said 2-((1-methylpropyl)amino)ethanol, the suspension conductivity change is not more than 70 µS/cm per pH unit, and preferably is not more than 50 µS/cm per pH unit. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time da nakon dodavanja navedenog 2-((1-metilpropil)amino)etanola, promjena vodljivosti nije veća od 70 µS/cm po jedinici pH, a poželjno nije veća od 50 µS/cm po jedinici pH.
Method according to any one of the preceding claims, characterized in that following the addition of said 2-((1-methylpropyl)amino)ethanol, the suspension conductivity does not change by more than 10 %, preferably does not change by more than 6 %, and more preferably does not change by more than 3 %. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time da se nakon dodavanja navedenog 2-((1-metilpropil)amino)etanola, promjena vodljivosti suspenzije ne mijenja za više od 10 %, poželjno se ne mijenja za više od 6 %, poželjnije se ne mijenja za više od 3 %.
Method according to any one of the preceding claims, characterized in that said calcium carbonate-comprising material comprises at least 50 %, preferably at least 80 %, and more preferably at least 98 %, by weight of calcium carbonate relative to the total weight of said calcium carbonate-comprising material. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time da navedeni materijal koji sadrži kalcijev karbonat sadrži najmanje 50 %, poželjno najmanje 80 % i poželjnije najmanje 98 %, po težini kalcijevog karbonata u odnosu na ukupnu težinu navedenog materijala koji sadrži kalcijev karbonat.
Method according to any one of the preceding claims, characterized in that the calcium carbonate of said carbonate-comprising material is a precipitated calcium carbonate (PCC), a natural ground calcium carbonate (NGCC), a surface-reacted calcium carbonate (SRCC), or a mixture thereof. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time da je navedeni materijal koji sadrži kalcijev karbonat istaloženi kalcijev karbonat (PCC), prirodna ruda kalcijevog karbonata (NGCC), površinski-izreagirani kalcijev karbonat (SRCC) ili njihova smjesa.
Method according to any one of the preceding claims, characterized in that said 2-((1-methylpropyl)amino)ethanol is added prior to, during or after, and preferably after, a step of grinding said calcium carbonate-comprising material in said suspension. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time da je navedeni 2-((1-metilpropil)amino)etanol dodan prije, za vrijeme ili nakon, poželjno nakon koraka mrvljenja navedenog materijala koji sadrži kalcijev karbonat u navedenu suspenziju.
Method according to any one of the preceding claims, characterized in that said 2-((1-methylpropyl)amino)ethanol is added to the dry form of said calcium carbonate-comprising material, and is optionally dry ground therewith before forming said suspension of calcium carbonate-comprising material. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time da je navedeni 2-((1-metilpropil)amino)etanol dodan suhom obliku materijala koji sadrži kalcijev karbonat i prema izboru je pored toga potpuno osušen prije stvaranja navedene suspenzije materijala koji sadrži kalcijev karbonat.
Method according to claim 17, characterized in that following addition of said 2-((1-methylpropyl)amino)ethanol to said suspension, the suspension is introduced in a container or unit up to a level determined by measurement of the suspension conductivity. 
Postupak u skladu s patentnim zahtjevom 17, naznačen time da se, nakon dodavanja navedenog 2-((1-metilpropil)amino)etanola u navedenu suspenziju, suspenzija dodaje u spremnik ili jedinicu do razine određene mjerenjem vodljivosti suspenzije.
Method according to claim 17, characterized in that following addition of said 2-((1-methylpropyl)amino)ethanol to said suspension, the suspension is passed through a passage having a suspension throughput regulated as a function of the suspension conductivity. 
Postupak u skladu s patentnim zahtjevom 17, naznačen time da nakon dodavanja navedenog 2-((1-metilpropil)amino)etanola u navedenu suspenziju, suspenzija prolazi kroz prolaz koji ima protok otopine reguliran kao funkciju vodljivosti suspenzije.
Method according to any one of the preceding claims, characterized in that the suspension conductivity change is not more than 50 µS/cm per pH unit and preferably is not more than 20 µS/cm per pH unit. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time da promjena vodljivosti otopine nije veća od 50 µS/cm po jedinici pH i poželjno nije veća od 20 µS/cm po jedinici pH.
A pharmaceutical composition for use in suppressing or reducing subcutaneous injection site reactions in a subject of a subcutaneously administered oligonucleotide, said pharmaceutical composition comprising: 
Farmaceutski sastav za uporabu u supresiji ili smanjenju reakcija na mjestu subkutanog injiciranja kod subjekta podvrgnutog subkutanoj primjeni oligonukleotida, navedeni farmaceutski sastav obuhvaća:
A pharmaceutical composition for use according to claim 1, wherein said linkage between two or more oligonucleotides occurs at the non-bridging oxygen (or sulphur in the case of phosphorothioation) atoms in the phosphosdiester linkage, and wherein said oligonucleotide is selected from the following Table: 
Farmaceutski sastav za uporabu u skladu s patentnim zahtjevom 1, pri čemu se navedena veza između dva ili više nukleotida pojavljuje na nevezujućim atomima kisika (ili sumpora u slučaju fosforotioacije) u fosfodiesterskoj vezi, i pri čemu je navedeni oligonukleotid odabran iz sljedeće tablice:
A pharmaceutical composition for use according to claims 1 or 2, wherein said divalent metal cation is calcium. 
Farmaceutski sastav za uporabu u skladu s patentnim zahtjevima 1 ili 2, pri čemu je navedeni divalentni metalni kation kalcij.
A pharmaceutical composition for use according to claims 1 or 2, wherein said divalent metal cation is magnesium. 
Farmaceutski sastav za uporabu u skladu s patentnim zahtjevima 1 ili 2, pri čemu je navedeni divalentni metalni kation magnezij.
A pharmaceutical composition for use according to claims 1 or 2, wherein said divalent metal cation is cobalt, iron (2+), manganese, copper or zinc. 
Farmaceutski sastav za uporabu u skladu s patentnim zahtjevima 1 ili 2, pri čemu je navedeni divalentni metalni kation kobalt, željezo (2+), mangan, bakar ili cink.
A pharmaceutical composition for use according to any one of claims 1 and 3 to 5, wherein said chelate complex comprises at least one double stranded oligonucleotide. 
Farmaceutski sastav za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 i 3 do 5, pri čemu se navedeni kompleks kelata sastoji od najmanje jednog dvolančanog oligonukleotida.
A pharmaceutical composition for use according to any one of claims 1 to 6, wherein said chelate complex comprises at least one fully phosphorothioated oligonucleotide. 
Farmaceutski sastav za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 6, pri čemu se navedeni kompleks kelata sastoji od najmanje jednog potpuno fosfototioatnog oligonukleotida.
A pharmaceutical composition for use according to any one of claims 1 to 7, wherein said chelate complex comprises at least one oligonucleotide with one 2' modified ribose. 
Farmaceutski sastav za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 7, pri čemu se navedeni kompleks kelata sastoji od najmanje jednog oligonukleotida s jednom 2' modificiranom ribozom.
A pharmaceutical composition for use according to any one of claims 1 to 8, wherein said chelate complex comprises oligonucleotide selected from the group consisting of SEQ ID NOs: 3 to 14. 
Farmaceutski sastav za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 8, pri čemu se navedeni kompleks kelata sastoji od oligonukleotida odabranih iz grupe koja se sastoji od SEQ ID NO: 3 do 14.
Providing granulated darunavir by; mixing water and Hypromellose 2910 15 mPa.s, spraying this first mixture on a powder of darunavir or a pharmaceutically acceptable salt or solvate thereof, and drying the so obtained darunavir granulate 
osiguravanje granuliranog darunavira pomoću: miješanja vode i hipromeloze 2910 15 mPa.s, raspršivanje prve smjese na prah darunavira ili njegovu farmaceutski prihvatljivu sol ili solvat, te sušenje tako dobivenog granulata darunavira
Adding granulated darunavir to the mixture and subsequent dry-blending 
dodavanje granuliranog darunavira u smjesu i zatim suho miješanje
Adding a lubricant and mixing until homogeneous, 
dodavanje lubrikanta i miješanje do homogenog stanja,
Effervescent tablet for the extemporaneous preparation of a suspension suitable for inhalatory administration comprising at least one water-insoluble active principle and excipients suitable for inhalatory administration comprising: 
Šumeća tableta namijenjena improviziranoj pripravi suspenzije pogodne za inhalacijsku primjenu koja sadrži najmanje jednu aktivnu tvar netopivu u vodi i pomoćne tvari pogodne za inhalacijsku primjenu, naznačena time što sadrži:
wherein said water-insoluble active principle has been micronized to a particle size between 0.5 to 7 µm and wherein said effervescent tablet, once added to water or to an aqueous solution, disaggregates until obtaining said extemporaneous suspension suitable for inhalatory administration, in which the original particle size distribution of said water insoluble active principle is maintained. 
neionske ili ionske surfaktante, gdje je navedena aktivna tvar netopiva u vodi mikronizirana do veličine čestica između 0,5 i 7 µm i gdje se navedena šumeća tableta, kada se doda u vodu ili u vodenu otopinu, raspada dok se ne dobije navedenu improviziranu suspenziju pogodnu za inhalacijsku primjenu, u kojoj se čuva izvorna raspodjela veličine čestica navedene aktivne tvari netopive u vodi.
Effervescent tablet according to claims 1 or 2, wherein said active principle is selected from the group consisting of beclomethasonedipropionate, fluticasone propionate, budesonide, flunisolide, betamethasone, triamcinolone, mometasone, ciclesonide and sobrerol. 
Šumeća tableta u skladu s patentnih zahtjeva 1 ili 2, naznačena time što se navedena aktivna tvar bira iz skupine koju čine beklometazon-dipropionat, flutikazon-propionat, budezonid, flunizolid, betametazon, triamcinolon, mometazon, ciklezonid i sobrerol.
and R21, taken together with the nitrogen atom to which they are attached, form an unsubstituted or substituted 5-6 membered heterocyclyl ring containing 1-2 heteroatoms selected from the group consisting of N and O; 
i R21, zajedno sa atomom azota za koji su vezani, obrazuju nesupstituirani ili supstituirani heterociklični prsten s 5-6 članova koji sadrži 1-2 heteroatoma izabrana iz grupe koju čine N i O;
wherein said unsubstituted or substituted 5-6 membered heterocyclyl ring formed by R20 and R21 and said unsubstituted or substituted 5-6 membered heterocyclyl ring of R23 are each independently unsubstituted or substituted with a C1-2 alkyl, a pharmaceutically acceptable carrier or excipient and at least one additional therapeutic agent. 
i što su navedeni nesupstituirani ili supstituirani heterociklični prsten s 5-6 članova oblikovani od strane R20 i R21 i naveden nesupstituiran ili supstituiran heterociklični prsten s 5-6 članova oblikovan od R23, nezavisno nesupstituirani ili supstituirani s C1-2 alkil radikalom, koja dalje sadrži farmaceutski prihvatljiv nosač ili ekscipijens i najmanje jedan dodatni terapijski agens izabran iz grupe koju čine nukleotidni inhibitori HIV reverzne transkriptaze.
and R21, taken together with the nitrogen atom to which they are attached, form a 5-6 membered heterocyclyl ring containing 1-2 heteroatoms selected from the group consisting of N and O; 
i R21, zajedno s atomom dušika za koji su vezani, formiraju heterociklični prsten s 5-6 članova koji sadrži 1-2 heteroatoma izabrana iz grupe koju čine N i O;
A controlled release soft capsule having a shell and a matrix fill comprising an active ingredient or drug, wherein the matrix fill consists of two phases in the form of an emulsion, wherein the emulsion comprises a hydrophilic internal phase consisting essentially of polyethylene glycol of molecular weight ranging from about 200 to about 8000, methyl cellulose and an active ingredient or drug and a lipid or lipophilic external phase; and wherein the ratio of the internal phase to external phase is from about 0.5:10 to about 1:1 by weight. 
Mekana kapsula s kontroliranim otpuštanjem koja sadrži omotač i ispunu matrice koja sadrži aktivni sastojak ili lijek, naznačena time da se ispuna matrice sastoji od dvije faze u obliku emulzije, pri čemu emulzija sadrži hidrofilnu unutrašnju fazu koja uglavnom sadrži polietilen glikol s molekularnom težinom u rasponu od oko 200 do oko 8000, metil celulozu i aktivni sastojak ili lijek, te lipidnu ili lipofilnu vanjsku fazu; te pri čemu omjer unutrašnje faze prema vanjskoj fazi je od oko 0.5:10 do oko 1:1 težinski.
The controlled release soft capsule of claim 1, wherein the external phase comprises a vegetable oil, hydrogenated vegetable oil, fatty acid, wax, fatty acid ester, or a combination thereof. 
Mekana kapsula s kontroliranim otpuštanjem prema zahtjevu 1, naznačena time da vanjska faza sadrži biljno ulje, hidrogenirano biljno ulje, masnu kiselinu, vosak, ester masne kiseline, ili njihovu kombinaciju.
The controlled release soft capsule of claim 9, wherein the active ingredient or drug is in the form of solid particles. 
Mekana kapsula s kontroliranim otpuštanjem prema zahtjevu 9, naznačena time da je aktivni sastojak ili lijek u obliku krutih čestica.
The controlled release soft capsule of any one of the preceding claims, wherein the active ingredient or drug is selected from the group consisting of anti-asthmatics, narcotic analgesics, narcotic antagonists, and cardiovascular drugs and/or is selected from the group consisting of diltiazem, nifedipine, oxycodone, morphine, morphine analogues, and morphine antagonists. 
Mekana kapsula s kontroliranim otpuštanjem prema bilo kojem od zahtjeva, naznačena time da se aktivni sastojak ili lijek bira iz skupine koju čine lijekovi protiv astme, narkotički analgetici, antagonisti narkotika, te kardiovaskularni lijekovi i/ili se bira iz skupine koju čine diltiazem, nifedipin, oksikodon, morfin, analozi morfina, i antagonisti morfina.
forming an emulsion from the resulting mixture by subjecting the mixture to mechanical forces generated by a propeller mixer, a homogenizer, or a microfluidizer; 
stvaranje emulzije iz dobivene smjese podvrgavanjem smjese mehaničkim silama koje su generirane s propelerskom miješalicom, homogenizatorom, ili mikrofluidizatorom;
encapsulating the emulsion using a rotary die encapsulation machine to form the controlled release capsule. 
inkapsuliranje emulzije korištenjem rotacijskog kalupnog stroja za kapsuliranje kako bi se dobila kapsula s kontroliranim otpuštanjem.
The composition of claim 4 which is suitable for topical administration. 
Pripravak u skladu s patentnim zahtjevom 4, naznačen time što je pogodan za topikalnu primjenu.
A compound for use according to claim 6 wherein said autoimmune disease is a skin disorder, multiple sclerosis, rheumatoid arthritis, psoriatic arthritis, juvenile arthritis, type I diabetes, lupus, inflammatory bowel disease, Crohn's disease, myasthenia gravis, immunoglobulin nephropathies, myocarditis, or autoimmune thyroid disorder. 
Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 6, naznačen time što je navedena autoimuna bolest poremećaj kože, multipla skleroza, reumatoidni artritis, psorijatični artritis, mladenački artritis, dijabetes tip I, lupus, upalna crijevna bolest, Crohnova bolest, miastenija gravis, imunoglobulinske nefropatije, miokarditis ili autoimuni poremećaj štitnjače.
A compound for use according to claim 7 wherein said autoimmune disease is a skin disorder, and is atopic dermatitis, psoriasis, skin sensitization, skin irritation, skin rash, contact dermatitis or allergic contact sensitization. 
Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 7, naznačen time što je navedena autoimuna bolest poremećaj kože, te je atopični dermatitis, psorijaza, sensibilizacija kože, iritacija kože, osip na koži, kontaktni dermatitis ili alergijska kontaktna sensibilizacija.
a memory; and a processor in communications with the memory, wherein the computer system is configured to perform a method, said method comprising: 
memoriju; i procesor u komunikaciji s memorijom, pri čemu je računalni sustav konfiguriran za izvođenje metode, koja obuhvaća:
obtaining by a program an indication of a warning track facility installed (700) within the computing environment, the warning track facility to provide to the program a warning track grace period to perform a function; 
pribavljanje indikacije o instaliranoj opremi za zonu upozorenja (700) unutar računalnog okoliša, oprema zone upozorenja pruža programu dodatni vremenski period u zoni upozorenja za izvođenje funkcije;
initiating, by the program based on obtaining the indication that the warning track facility is installed, registration of the program for the warning track facility (702), the registration comprising an unsolicited registration request indicating that the program understands a protocol of the warning track facility and intends to participate in the warning track facility; 
započinjući, pomoću programa koji se temelji na pribavljanju indikacije kako je oprema zone upozorenja instalirana, registracija programa za opremu zone upozorenja (702), registracija obuhvaća netraženi zahtjev za registraciju koji upućuje na to da program razumije protokol opreme zone upozorenja i namjerava sudjelovati u opremi zone upozorenja;
receiving by the program a warning track notification indicating the warning track grace period has begun, the registration of the program for the warning track facility being a prerequisite to receiving the warning track notification, wherein if the program is not registered, then no grace period is offered; and 
prihvaćanje obavijesti o zoni upozorenja koja upućuje na to da je dodatno razdoblje za zonu upozorenja počelo, registracija programa za opremu zone upozorenja pretpostavka je prihvata notifikacije o zoni upozorenja, pri čemu ukoliko program nije registriran, nema ponude dodatnog razdoblja;
based on the warning track notification, at least initiating by the program the function within the warning track grace period. 
i temeljem notifikacije o zoni upozorenja, barem započinjanjem funkcije unutar dodatnog razdoblja za zonu upozorenja.